Compare Heron Therapeutics Inc (HRTX) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Trip.com Group Ltd — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Trip.com Group Ltd trades at $44.19 (market cap $28.12B). The key difference: Trip.com Group Ltd is far larger — about 307.5× Heron Therapeutics Inc's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | TCOM | |
|---|---|---|
Market Cap | $91.46M | $28.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.96 | $78.96 |
52-Week Low | $0.39 | $39.84 |
Enterprise Value | $189.36M | $20.82B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
TCOM trades at $44.15, up 4.0% over 24 hours but facing near-term pressure after recent earnings misses and regulatory scrutiny. The stock shows strong fundamentals with a P/E of 6.38 and net income margin of 48.65%, supported by robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Technical indicators signal a bearish trend with resistance at $44-$45, while analyst consensus remains bullish with a $56.72 price target despite recent guidance concerns.
The outlook balances high profitability and undervaluation against regulatory risks and slowing growth guidance. Investment appeal lies in its dominant market position and cash flow strength, but investors face headwinds from antitrust investigations and margin pressure. The stock's current discount to analyst targets presents opportunity if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
